SPY295.44+0.56 0.19%
DIA244.88-0.14 -0.06%
IXIC9,324.59+39.71 0.43%

BMO Capital Maintains Outperform on Evelo Biosciences, Lowers Price Target to $21

BMO Capital maintains Evelo Biosciences (NASDAQ:EVLO) with a Outperform and lowers the price target from $24 to $21.

Benzinga · 05/12/2020 14:55

BMO Capital maintains Evelo Biosciences (NASDAQ:EVLO) with a Outperform and lowers the price target from $24 to $21.